Most just lately, it's been determined that conolidine and the above derivatives act on the atypical chemokine receptor 3 (ACKR3. Expressed in comparable locations as classical opioid receptors, it binds to a wide array of endogenous opioids. Not like most opioid receptors, this receptor acts as a scavenger and will not activate a second messenger